Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 17-18/2016

01.09.2016 | original article

The relationship between visfatin, liver inflammation, and acute phase reactants in chronic viral hepatitis B

verfasst von: MD Enver Yüksel, MD Erdem Akbal, MD Erdem Koçak, MD Ömer Akyürek, MD Seyfettin Köklü, Fuat Ekiz, Barış Yılmaz

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 17-18/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Chronic viral hepatitis B (CHB) is an important cause of morbidity and mortality. Adipokine stimulation might play an important role in the pathogenesis of chronic inflammation. The aim of this study was to evaluate serum visfatin concentrations and the relationship between visfatin, fibrosis, liver inflammation, and acute phase reactants in CHB patients.
The sampling universe of the study consisted of 41 CHB patients and 25 healthy controls. All patients had positive hepatitis B surface antigen (Hepatitis e antigen (HBeAg) positive n: 7, n: 34 HBeAg negative) for at least 6 months and detectable serum HBV DNA. Serum visfatin concentrations were significantly higher in the CHB patients [18.0 ± 10.9 ng dL−1] than in the healthy controls [9.4 ± 1.6 ng dL−1] [P < 0.001]. On the other hand, fibrinogen and haptoglobin concentrations were significantly lower in CHB patients. A strong negative correlation was observed between serum visfatin concentration, haptoglobin, and fibrinogen levels; however, there was no significant correlation between visfatin, glucose, alanine aminotransferase, aspartate aminotransferase, BMI, Knodell score, fibrosis score, hepatitis B virus DNA, sedimentation, and C-reactive protein. Visfatin concentrations were elevated and visfatin was negatively correlated with haptoglobin and fibrinogen levels in CHB patients.
Literatur
1.
Zurück zum Zitat Li X, Ren N, Ling W, Chen F, Zhang W, Fan X, Tian M, Zhang T, Li B, Pfeffer LM, Wu H, Zhang J. Adiponectin and its receptors in chronic hepatitis B patients with metabolic syndrome in china. Hepatogastroenterology. 2012;59:1735–43. CrossRefPubMed Li X, Ren N, Ling W, Chen F, Zhang W, Fan X, Tian M, Zhang T, Li B, Pfeffer LM, Wu H, Zhang J. Adiponectin and its receptors in chronic hepatitis B patients with metabolic syndrome in china. Hepatogastroenterology. 2012;59:1735–43. CrossRefPubMed
2.
Zurück zum Zitat Wong VW, Wong GL, Yu J, Choi PC, Chan AW, Chan HY, Chu ES, Cheng AS, Chim AM, Chan FK, Sung JJ, Chan HL. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol. 2010;105:132–8. CrossRefPubMed Wong VW, Wong GL, Yu J, Choi PC, Chan AW, Chan HY, Chu ES, Cheng AS, Chim AM, Chan FK, Sung JJ, Chan HL. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol. 2010;105:132–8. CrossRefPubMed
3.
Zurück zum Zitat Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–30. CrossRefPubMed Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–30. CrossRefPubMed
4.
Zurück zum Zitat Kukla M, Zwirska-Korczala K, Gabriel A, Waluga M, Warakomska I, Berdowska A, Rybus-Kalinowska B, Kalinowski M, Janczewska-Kazek E, Woźniak-Grygiel E, Kryczka W. Visfatin serum levels in chronic hepatitis C patients. J Viral Hepat. 2010;17:254–60. CrossRefPubMed Kukla M, Zwirska-Korczala K, Gabriel A, Waluga M, Warakomska I, Berdowska A, Rybus-Kalinowska B, Kalinowski M, Janczewska-Kazek E, Woźniak-Grygiel E, Kryczka W. Visfatin serum levels in chronic hepatitis C patients. J Viral Hepat. 2010;17:254–60. CrossRefPubMed
5.
Zurück zum Zitat Akbal E, Koçak E, Taş A, Yüksel E, Köklü S. Visfatin levels in nonalcoholic fatty liver disease. J Clin Lab Anal. 2012;26:115–9. CrossRefPubMed Akbal E, Koçak E, Taş A, Yüksel E, Köklü S. Visfatin levels in nonalcoholic fatty liver disease. J Clin Lab Anal. 2012;26:115–9. CrossRefPubMed
6.
Zurück zum Zitat Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damås JK, Haaland T, Løberg EM, Arntsen B, Birkeland K, Bjøro K, Ulven SM, Konopski Z, Nebb HI, Aukrust P, Halvorsen B. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2010;95:3039–47. CrossRefPubMed Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damås JK, Haaland T, Løberg EM, Arntsen B, Birkeland K, Bjøro K, Ulven SM, Konopski Z, Nebb HI, Aukrust P, Halvorsen B. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2010;95:3039–47. CrossRefPubMed
7.
Zurück zum Zitat Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, Velasco MC, Alvarez T, Pacheco D, González JM. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci. 2009;54:1772–7. CrossRefPubMed Aller R, de Luis DA, Izaola O, Sagrado MG, Conde R, Velasco MC, Alvarez T, Pacheco D, González JM. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci. 2009;54:1772–7. CrossRefPubMed
8.
Zurück zum Zitat Baranova A, Jarrar MH, Johnson A. Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C. Digestion. 2011;83:32–40. CrossRefPubMed Baranova A, Jarrar MH, Johnson A. Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C. Digestion. 2011;83:32–40. CrossRefPubMed
9.
Zurück zum Zitat Kukla M, Ciupińska-Kajor M, Kajor M, Wyleżoł M, Żwirska-Korczala K, Hartleb M, Berdowska A, Mazur W. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol J Pathol. 2010;61:147–53. PubMed Kukla M, Ciupińska-Kajor M, Kajor M, Wyleżoł M, Żwirska-Korczala K, Hartleb M, Berdowska A, Mazur W. Liver visfatin expression in morbidly obese patients with nonalcoholic fatty liver disease undergoing bariatric surgery. Pol J Pathol. 2010;61:147–53. PubMed
10.
Zurück zum Zitat Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412–21. CrossRefPubMed Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412–21. CrossRefPubMed
11.
Zurück zum Zitat Ramadori G, Christ B. Cytokines and hepatic acute-phase response. Semin Liver Dis. 1999;19:141–55. CrossRefPubMed Ramadori G, Christ B. Cytokines and hepatic acute-phase response. Semin Liver Dis. 1999;19:141–55. CrossRefPubMed
12.
Zurück zum Zitat Gaddipati R, Sasikala M, Padaki N, Mukherjee RM, Sekaran A, Jayaraj-Mansard M, Rabella P, Rao-Guduru V, Reddy-Duvvuru N. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann Hepatol. 2010;9:266–70 PubMed Gaddipati R, Sasikala M, Padaki N, Mukherjee RM, Sekaran A, Jayaraj-Mansard M, Rabella P, Rao-Guduru V, Reddy-Duvvuru N. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Ann Hepatol. 2010;9:266–70 PubMed
13.
Zurück zum Zitat European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85 CrossRef European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85 CrossRef
14.
Zurück zum Zitat Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Lago F, Gualillo O. What’s new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol. 2011;7:528–36. CrossRefPubMed Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Lago F, Gualillo O. What’s new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol. 2011;7:528–36. CrossRefPubMed
15.
Zurück zum Zitat Cheng PN, Tsai HW, Chiu YC, Ho CH, Wu IC, Chang TT. Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B. J Clin Virol. 2013;57(4):323–30. CrossRefPubMed Cheng PN, Tsai HW, Chiu YC, Ho CH, Wu IC, Chang TT. Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B. J Clin Virol. 2013;57(4):323–30. CrossRefPubMed
16.
Zurück zum Zitat Barbosa Vde S, Rêgo J, Antônio da Silva N. Possible role of adipokines in systemic lupus erythematosus and rheumatoid arthritis. Rev Bras Reumatol. 2012;52:278–87. CrossRefPubMed Barbosa Vde S, Rêgo J, Antônio da Silva N. Possible role of adipokines in systemic lupus erythematosus and rheumatoid arthritis. Rev Bras Reumatol. 2012;52:278–87. CrossRefPubMed
17.
Zurück zum Zitat Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor [PBEF]/visfatin: a novel mediator of innate immunity. J Leukoc Biol. 2008;83:804–16. CrossRefPubMed Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor [PBEF]/visfatin: a novel mediator of innate immunity. J Leukoc Biol. 2008;83:804–16. CrossRefPubMed
18.
Zurück zum Zitat Lalor PF, Shields P, Grant AJ, Adams DH. Recruitment of lymphocytes to the human liver. Immunol Cell Biol. 2002;80:52–64. CrossRefPubMed Lalor PF, Shields P, Grant AJ, Adams DH. Recruitment of lymphocytes to the human liver. Immunol Cell Biol. 2002;80:52–64. CrossRefPubMed
19.
Zurück zum Zitat Ziolkowski A, Wylezol M, Kukla M. Factors associated with steatosis and necroinflammatory activity in morbidly obese patients with non-alcoholic fatty liver disease. Pol J Environ Stud. 2005;14(Suppl 2):417–20. Ziolkowski A, Wylezol M, Kukla M. Factors associated with steatosis and necroinflammatory activity in morbidly obese patients with non-alcoholic fatty liver disease. Pol J Environ Stud. 2005;14(Suppl 2):417–20.
20.
Zurück zum Zitat Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol. 2005;2(2):92–100. PubMed Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol. 2005;2(2):92–100. PubMed
21.
Zurück zum Zitat Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology. 2008;15:91–101. CrossRefPubMed Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology. 2008;15:91–101. CrossRefPubMed
22.
Zurück zum Zitat Siagris D, Vafiadis G, Michalaki M, Lekkou A, Starakis I, Makri M, Margaritis V, Christofidou M, Tsamandas AC, Labropoulou-Karatza C. Serum adiponectin in chronic hepatitis C and B. J Viral Hepat. 2007;14(8):577–83. CrossRefPubMed Siagris D, Vafiadis G, Michalaki M, Lekkou A, Starakis I, Makri M, Margaritis V, Christofidou M, Tsamandas AC, Labropoulou-Karatza C. Serum adiponectin in chronic hepatitis C and B. J Viral Hepat. 2007;14(8):577–83. CrossRefPubMed
23.
Zurück zum Zitat Zwirska-Korczala, K., Kukla, M., Ziolkowski, A., Janczewska-Kazek, E., Berdowska, A., Sitkiewicz, A., Dziambor, A., Wiczkowski, A., Gabriel, A. Leptin, neopterin and hepatocyte growth factor as markers of fibrosis and inflammatory activity in chronic hepatitis C. Exp Clin Hepatol. 2005;1(2):60–5. Zwirska-Korczala, K., Kukla, M., Ziolkowski, A., Janczewska-Kazek, E., Berdowska, A., Sitkiewicz, A., Dziambor, A., Wiczkowski, A., Gabriel, A. Leptin, neopterin and hepatocyte growth factor as markers of fibrosis and inflammatory activity in chronic hepatitis C. Exp Clin Hepatol. 2005;1(2):60–5.
24.
Zurück zum Zitat Petit JM, Minello A, Brisard C, Galland F, Duvillard L, Verges B, Hillon P. Plasma resistin concentration, and steatosis and insulin sensitivity in hepatitis C virus-infected patients. J Gastroenterol Hepatol. 2006;21(3):624. CrossRefPubMed Petit JM, Minello A, Brisard C, Galland F, Duvillard L, Verges B, Hillon P. Plasma resistin concentration, and steatosis and insulin sensitivity in hepatitis C virus-infected patients. J Gastroenterol Hepatol. 2006;21(3):624. CrossRefPubMed
25.
Zurück zum Zitat Shima M 1, Nakao K, Kato Y, Nakata K, Ishii N, Nagataki S. Comparative study of C-reactive protein in chronic hepatitis B and chronic hepatitis C. Tohoku J Exp Med. 1996;178(3):287–97. Shima M 1, Nakao K, Kato Y, Nakata K, Ishii N, Nagataki S. Comparative study of C-reactive protein in chronic hepatitis B and chronic hepatitis C. Tohoku J Exp Med. 1996;178(3):287–97.
26.
Zurück zum Zitat Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178(3):1748–58. CrossRefPubMed Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178(3):1748–58. CrossRefPubMed
27.
Zurück zum Zitat Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. J Cell Mol Med. 2004;8(4):445–54. CrossRefPubMed Ding WX, Yin XM. Dissection of the multiple mechanisms of TNF-alpha-induced apoptosis in liver injury. J Cell Mol Med. 2004;8(4):445–54. CrossRefPubMed
28.
Zurück zum Zitat Wolf D, Hallmann R, Sass G, Sixt M, Küsters S, Fregien B, Trautwein C, Tiegs G. TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR-1-relevance for concanavalin A-induced hepatitis. J Immunol. 2001;166(2):1300–7. CrossRefPubMed Wolf D, Hallmann R, Sass G, Sixt M, Küsters S, Fregien B, Trautwein C, Tiegs G. TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR-1-relevance for concanavalin A-induced hepatitis. J Immunol. 2001;166(2):1300–7. CrossRefPubMed
29.
Zurück zum Zitat Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH, Jang HO, Yun I, Kim KW, Kwon YG, Yoo MA, Bae MK. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta. 2008;1783(5):886–95. CrossRefPubMed Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, Koo TH, Jang HO, Yun I, Kim KW, Kwon YG, Yoo MA, Bae MK. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta. 2008;1783(5):886–95. CrossRefPubMed
Metadaten
Titel
The relationship between visfatin, liver inflammation, and acute phase reactants in chronic viral hepatitis B
verfasst von
MD Enver Yüksel
MD Erdem Akbal
MD Erdem Koçak
MD Ömer Akyürek
MD Seyfettin Köklü
Fuat Ekiz
Barış Yılmaz
Publikationsdatum
01.09.2016
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 17-18/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0723-9